Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825

被引：7

作者：

Abruzzese, Elisabetta ^{[1
]}

Del Poeta, Giovanni ^{[1
]}

Barbato, Rosanna ^{[1
]}

Fratoni, Stefano ^{[1
]}

Trawinska, Malgorzata M. ^{[1
]}

Zangrilli, Daniela ^{[1
]}

Coletta, Angela M. ^{[1
]}

Patroi, Ivona M. ^{[1
]}

Francesconi, Francesca ^{[1
]}

Santeusanio, Giuseppe ^{[1
]}

De Fabritiis, Paolo ^{[1
]}

Arnadori, Sergio ^{[1
]}

机构：

[1] Univ Roma Tor Vergata, S Eugenio Hosp, I-00144 Rome, Italy

来源：

BLOOD | 2006年 / 107卷 / 11期

关键词：

D O I：

10.1182/blood-2005-11-4707

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

收藏

页码：4571 / 4572

页数：2

相关论文

共 10 条

[1]

CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: Two case reports [J].

Abruzzese, E ;

Cantonetti, M ;

Morino, L ;

Orlandi, G ;

Tendas, A ;

Del Principe, MI ;

Masi, M ;

Amadori, S ;

Orlandi, A ;

Anemona, L ;

Campione, E .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4256-4258

[2]

Breccia Massimo, 2004, Haematologica, V89, pECR11

[3]

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance [J].

Burgess, MR ;

Skaggs, BJ ;

Shah, NP ;

Lee, FY ;

Sawyers, CL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (09) :3395-3400

[4]

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia [J].

Donato, NJ ;

Wu, JY ;

Stapley, J ;

Lin, H ;

Arlinghaus, R ;

Aggarwal, B ;

Shishodin, S ;

Albitar, M ;

Hayes, K ;

Kantarjian, H ;

Talpaz, M .

CANCER RESEARCH, 2004, 64 (02) :672-677

[5]

Hochhaus A, 2001, SCIENCE, V293, P2163

[6]

Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays [J].

Lombardo, LJ ;

Lee, FY ;

Chen, P ;

Norris, D ;

Barrish, JC ;

Behnia, K ;

Castaneda, S ;

Cornelius, LAM ;

Das, J ;

Doweyko, AM ;

Fairchild, C ;

Hunt, JT ;

Inigo, I ;

Johnston, K ;

Kamath, A ;

Kan, D ;

Klei, H ;

Marathe, P ;

Pang, SH ;

Peterson, R ;

Pitt, S ;

Schieven, GL ;

Schmidt, RJ ;

Tokarski, J ;

Wen, ML ;

Wityak, J ;

Borzilleri, RM .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (27) :6658-6661

[7]

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants [J].

O'Hare, T ;

Walters, DK ;

Stoffregen, EP ;

Jia, TP ;

Manley, PW ;

Mestan, J ;

Cowan-Jacob, SW ;

Lee, FY ;

Heinrich, MC ;

Deininger, MWN ;

Druker, BJ .

CANCER RESEARCH, 2005, 65 (11) :4500-4505

[8]

SHAH N, 1942, CANCER CELL, V289, P1938

[9]

Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

[10]

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia [J].

Soverini, S ;

Martinelli, G ;

Rosti, G ;

Bassi, S ;

Amabile, M ;

Poerio, A ;

Giannini, B ;

Trabacchi, E ;

Castagnetti, F ;

Testoni, N ;

Luatti, S ;

de Vivo, A ;

Cilloni, D ;

Izzo, B ;

Fava, M ;

Abruzzese, E ;

Alberti, D ;

Pane, F ;

Saglio, G ;

Baccarani, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4100-4109